Release Summary

With More than One-Year Follow-Up, Merck’s KEYTRUDA Shows Continued Overall Survival Benefit Over Chemotherapy as Second-Line Treatment for Advanced Urothelial Carcinoma Patients Post-Platinum Failure

Merck